CCND1 and melanoma: Treatment of melanoma cells with epigallocatechin gallate leads to a reduction in cyclin D1 and cdk2 protein levels, as well as stimulation of the cyclin kinase inhibitors (ckis) and p27KIP1.125 Combretastatin (124) is the new molecule of vascular disrupting medicines that target tumor blood channels and prevent angiogenesis.